Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2009. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share ownership changes and does not contain financial performance data.
Material Changes
The material change disclosed is the acquisition of Ordinary shares by eight individuals under the Company's Share Reward Plan on September 9, 2009. The transactions involved:
- Share Price: £11.78 per Ordinary share.
- Participants: Mr A P Witty, Mr J S Heslop, Mr S M Bicknell, Mr E J Gray, Mr S A Hussain, Mr D Learmouth, Mr D S Redfern, and Ms C Thomas.
- Transaction Details: Each individual acquired 11 shares via the partnership element (personal contribution) and 11 shares via the matching element (Company contribution).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific share transactions described above in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares acquired by each named director (22 shares per person: 11 personal + 11 company match).
- Confirm the transaction date of September 9, 2009, and the notification date of September 10, 2009.
- Validate the share price of £11.78 used for the Share Reward Plan transactions.
- Ensure the filing aligns with the company's ongoing compliance with Disclosure and Transparency Rules.